Search
Tinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalTinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500...
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigational[L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800]
Agalsidase beta
go.drugbank.com/drugs/DB00103ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.
Bimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigationalBimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution an...
Calcium lactate
go.drugbank.com/drugs/DB13231ApprovedVet approvedCalcium lactate is a salt that consists of two lactate anions for each calcium cation (Ca2+). It is prepared commercially by the neutralization of lactic acid with calcium carbonate or calcium hydroxide. Approved by the FDA as a direct f...
Allylestrenol
go.drugbank.com/drugs/DB01431InvestigationalIt is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a m...
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigationalLazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-sma...
Agalsidase alfa
go.drugbank.com/drugs/DB15874ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.